Ampio announces active IND for Optina for treatment of DME Ampio Pharmaceuticals announced that the FDA has accepted the company's IND for Optina for the treatment of Diabetic Macular Edema, or DME. Ampio plans to commence enrollment in a clinical trial in Q1. The FDA granted Optina 505 b 2 status in July, 2012. Drugs designated under this pathway can be approved on a single trial.
News For AMPE From The Last 14 Days
Check below for free stories on AMPE the last two weeks.